Search results
Showing 46 to 60 of 92 results for venous thromboembolism
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
Research into the long-term treatment effects of rivaroxaban is needed.
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Number TA287 Date issued June 2013 Other
details Comes from guidance Apixaban for preventing venous thromboembolism after hip or knee replacement surgery Number TA245
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Number TA287 Date issued June 2013 Other
Obesity may as much as double a person's risk of developing hospital-acquired VTE,therefore most obese people will need prophylaxis....
on oxygenation and lead to a reduction in complications such as venous thromboembolism and hypostatic pneumonia. There could be benefits...
inexpensive. Source guidance details Comes from guidance Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep...
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
DOAC Dipstick for detecting direct oral anticoagulants (MIB248)
NICE has developed a medtech innovation briefing (MIB) on DOAC Dipstick for detecting direct oral anticoagulants .
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
This guidance has been updated and replaced by NICE guideline CG92.
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.